Delay in 2003 drug prices may signal Medicare policy shift

Article Overview

This article examines a possible shift in Medicare policy for physician-administered drug payment amounts, focusing on CMS actions, carrier-level pricing administration, and the prospect of a national drug pricing approach. It also places the issue in the context of broader Medicare payment debates, including carrier consistency, reimbursement concerns for physician practices, and competing policy ideas discussed by Congress and medical specialty groups. The piece is relevant to physicians, practice managers, coders, reimbursement staff, and health policy readers who track Part B drug payment developments and Medicare administration.